US2010022610A1PendingUtilityA1
New Crystalline Forms
Est. expiryMar 23, 2026(expired)· nominal 20-yr term from priority
Inventors:Martin Bohlin
A61P 9/00A61P 35/00A61P 25/04A61P 25/22A61P 25/28A61P 25/16A61P 25/00A61P 25/14A61P 1/00C07D 235/08A61P 1/04A61K 31/4184
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a citric acid salt, a methanesulphonic acid salt, or a p-toluenesulphonic acid salt of said compound.
Claims
exact text as granted — not AI-modified1 - 34 . (canceled)
35 . A pharmaceutical composition comprising an ethanesulphonic acid salt of N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide having an X-ray powder diffraction pattern with specific peaks at d-values at 14.0, 7.0, 4.99, and 4.62 Å, in admixture with a pharmaceutically acceptable diluent or carrier.
36 . A pharmaceutical composition according to claim 35 , wherein said salt has an X-ray powder diffraction pattern with specific peaks at d-values at 14.0, 7.0, 4.99, and 4.62 Å, and as defined in Table 1 and FIG. 1
TABLE 1
d-value
Relative
(Å)
intensity
14.0
vs
9.6
vw
9.2
m
8.4
vw
7.8
s
7.7
s
4.77
m
4.62
vs
4.41
s
4.33
m
4.24
s
4.18
m
3.44
m
3.40
m
3.31
vw
3.28
m
3.10
m
3.05
mCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.